KeraStat Skin Therapy in Treating Radiation Dermatitis in Patients With Newly Diagnosed Stage 0-IIIA Breast Cancer

Inclusion Criteria:

• Newly diagnosed with breast carcinoma, stage 0-IIIA (including ductal carcinoma insitu [DCIS])

• Status post-lumpectomy, -quadrantectomy, or -mastectomy

• Plan to receive adjuvant radiation to the whole breast or chest wall +/- regionallymph nodes

• Total dose >= 40Gy

• Dose per fraction >= 1.8 use of 2-dimensional (2D), 3-dimensional (3D) conformal, orintensity-modulated radiation therapy (IMRT) treatment techniques allowed; skinsparing IMRT patients excluded; a daily fraction of 2.7 Gy to the whole breast issuggested for hypofractionated regimens

• Concurrent and sequential boost techniques are allowed for both standard andhypofractionated regimens

• Adjuvant hormonal therapy will be allowed prior to, during and/or after RT at thediscretion of a medical oncologist

• Targeted therapies such as Herceptin will be allowed prior to, during, and/or after RTat the discretion of the medical oncologist

• Patients who are able and willing to sign protocol consent form

Exclusion Criteria:

• Prior radiation to the involved breast or chest wall

• Concurrent chemotherapy; (patients may receive chemotherapy prior to radiation orfollowing radiation at the treating physician's discretion)

• Patients who underwent breast reconstruction following mastectomy (placement of tissueexpanders and implants are not allowed)

• Patients undergoing partial breast irradiation

• Patients who have undergone MammoSite® or any other form of brachytherapy

• Patients may not be concurrently enrolled in a protocol that involves treatment of theskin ie: applying lotions /moisturizers; protocols that do not involve treatment ofthe skin are allowed

• Patients who are pregnant or breastfeeding